Medicine & Life Sciences
Smoking Cessation
100%
Ecological Momentary Assessment
69%
Vulnerable Populations
66%
Pravastatin
61%
Atorvastatin
59%
Safety-net Providers
59%
Simvastatin
59%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
48%
Smoking
47%
Early Detection of Cancer
47%
Lung Neoplasms
39%
Stakeholder Participation
36%
Tobacco Use Cessation Devices
35%
Hyperlipidemias
33%
Coenzymes
31%
lipoprotein cholesterol
31%
Tobacco Products
30%
Withholding Treatment
30%
LDL Cholesterol
24%
Tobacco
23%
Oxidoreductases
22%
C-Reactive Protein
21%
Motivation
20%
Medically Underserved Area
19%
Comorbidity
19%
Guidelines
19%
Safety
15%
Income
14%
Counseling
14%
Population
14%
Demography
14%
Patient Participation
14%
Smoke
12%
glutaryl-coenzyme A
12%
Tomography
12%
Health
12%
Smokers
12%
Smartphone
11%
Documentation
11%
Therapeutics
11%
Tobacco Use Cessation
11%
Pharmaceutical Preparations
11%
Interleukin-6 Receptors
10%
Cross-Over Studies
10%
Logistic Models
10%
Triglycerides
9%
American Heart Association
8%
Diet
8%
Lipoproteins
6%
Fasting
6%
Social Sciences
smoking
46%
nicotine
28%
contingency
23%
incentive
18%
stakeholder
17%
methodology
12%
activation
12%
management
11%
health
11%
documentation
10%
clinician
10%
counseling
9%
time
8%
electronics
8%
household income
5%